Benign esophageal tumors

Benign esophageal tumors comprise a heterogeneous group of nonmalignant neoplastic lesions arising from the different tissue components of the esophageal wall. Although they account for a much smaller proportion than malignant neoplasms, they have significant clinical importance because of their possible symptomatic, diagnostic and management implications. These lesions may arise from smooth muscle, connective tissue, adipose tissue, blood vessels, intramural nerves or the mucosa, reflecting the complex histologic organization of the esophagus.

Biologically, benign esophageal tumors are characterized by generally slow growth, locally expansile behavior and absence of metastatic capacity. Nevertheless, their location within a narrow tubular organ may cause substantial functional impairment even when their dimensions are relatively limited, resulting in dysphagia, a foreign-body sensation or retrosternal pain. In many cases, particularly at an early stage, the lesions remain asymptomatic and are identified incidentally during endoscopic examinations performed for other reasons.

The diagnostic assessment and evaluation of local extent and clinical risk of benign esophageal tumors require a systematic approach integrating upper gastrointestinal endoscopy, endoscopic ultrasound to define the layer of origin and growth characteristics, and radiologic imaging in selected cases. Histologic diagnosis is often necessary to distinguish benign lesions from tumors with malignant potential or low-grade malignant neoplasms. Therapeutic management varies according to histologic type, size, symptoms and the patient’s condition, ranging from clinical observation to endoscopic or surgical treatment. In most cases, the prognosis is excellent.

The epidemiology of benign esophageal tumors is characterized by a low overall incidence and an uneven distribution among the different histologic types. Collectively, these lesions represent a small percentage of esophageal neoplasms and are far less frequent than carcinomas. Among benign tumors, leiomyoma is by far the most common form and accounts for most cases reported in clinical series.

Leiomyomas arise from smooth muscle in the esophageal wall and occur most frequently in the middle and distal thirds of the esophagus, where the muscular component is more prominent. Other benign forms, such as lipomas, fibromas, hemangiomas and squamous papillomas, are much rarer and are described mainly as isolated cases or in small series. Their true incidence may be underestimated because many lesions remain clinically silent and are never diagnosed.

From a demographic perspective, benign esophageal tumors may occur across a wide age range, with leiomyomas being more frequent in the fourth and fifth decades of life. Sex distribution is generally balanced or shows a slight male predominance, depending on the histologic type. Unlike malignant esophageal neoplasms, no relevant geographic differences have been documented.

Specific risk factors for the development of benign esophageal tumors are not well defined. In most cases, these lesions appear to arise sporadically without a clear association with environmental or behavioral exposures. Some forms, such as squamous papillomas, have been associated with chronic irritation of the esophageal mucosa, whereas no single etiologic determinant has been identified for mesenchymal tumors.

More rarely, certain lesions may occur in syndromic settings or in association with systemic conditions that predispose to mesenchymal proliferations, although this is exceptionally uncommon in the esophagus. Overall, the absence of clearly modifiable risk factors makes it difficult to establish specific primary-prevention strategies for these lesions, while early recognition in symptomatic patients remains central.

Population screening programs are not recommended for benign esophageal tumors because of their rarity and generally indolent course. The absence of specific noninvasive tests and their limited impact on mortality do not justify systematic screening in the general population.

Most benign tumors are identified incidentally during upper gastrointestinal endoscopy performed for nonspecific symptoms or follow-up of other esophageal diseases. In these cases, detection of a well-circumscribed subepithelial or mucosal lesion initiates a targeted diagnostic pathway designed to define its nature, size and layer of origin.

Endoscopic surveillance may be indicated in selected patients, particularly when the lesion is small, asymptomatic and lacks suspicious features. In such situations, periodic monitoring allows assessment of any growth over time and permits therapeutic intervention to be scheduled only if significant changes occur.

For larger benign tumors or symptomatic lesions, endoscopic ultrasound has a central role in follow-up because it allows monitoring of relationships with the deeper layers of the wall and early detection of atypical features that warrant diagnostic reassessment. Surveillance intervals are determined case by case and depend mainly on lesion size, layer of origin, behavior over time and the feasibility of obtaining a representative tissue sample.

After endoscopic or surgical treatment, surveillance is generally limited and intended to exclude residual disease or local recurrence, both of which are uncommon for most benign lesions after complete resection. In asymptomatic patients with documented radical removal, further examinations may not be necessary, while reassessment remains indicated if new symptoms develop.

Benign esophageal tumors comprise a heterogeneous group of nonmalignant lesions arising from the different structural components of the esophageal wall, including smooth muscle, connective tissue, blood vessels, nerves and submucosal glands. Although they represent a minority of esophageal diseases, they are clinically important because they may mimic malignant neoplasms clinically, endoscopically or radiologically and because local growth may cause complications.

Biologically, these lesions are characterized by slow, circumscribed growth, absence of metastatic capacity and no or minimal infiltrative behavior. Many benign tumors originate in the deep layers of the wall, particularly the muscularis propria or submucosa, and initially develop as subepithelial masses covered by intact mucosa. This growth pattern explains the frequent discrepancy between the true dimensions of the lesion and superficial endoscopic findings and supports the central role of endoscopic ultrasound in defining the layer of origin.

Leiomyoma is the most common benign esophageal neoplasm and arises from smooth-muscle cells of the muscularis propria or, less frequently, the muscularis mucosae. Its biology reflects a well-differentiated proliferation that is generally devoid of necrosis and has low mitotic activity. In this setting, the most important differential diagnosis is gastrointestinal stromal tumor, especially when the lesion arises from the muscularis propria, because a similar endoscopic appearance may correspond to different biological entities.

Other benign lesions arise from stromal or vascular components. Esophageal hemangiomas and vascular malformations are characterized by well-organized endothelial proliferations or ectatic vascular structures, and their clinical relevance is mainly related to the risk of bleeding. Lipomas arise from submucosal adipose tissue and appear as well-circumscribed, slow-growing masses. Fibromas originate from connective tissue and may appear as solid submucosal nodules. Schwannomas arise from Schwann cells of the intramural nerve plexuses and show a characteristic, orderly architecture.

At the molecular level, benign esophageal tumors, particularly leiomyomas, generally do not harbor the driver alterations typical of GISTs, such as KIT or PDGFRA mutations, which is useful in the differential diagnosis when representative tissue is available. More generally, when genetic alterations are present, they are not associated with the patterns of chromosomal instability or histologic signs of aggressiveness that suggest malignant behavior. Because the availability of systematic studies varies among rare entities, molecular findings must always be interpreted together with morphology, immunophenotype and clinical context.

Histologically, benign esophageal tumors show orderly architecture and a high degree of differentiation. Leiomyomas consist of interlacing bundles of spindle cells with elongated nuclei, fine chromatin and no significant atypia. Vascular lesions contain well-formed vascular channels or dilated vascular spaces. Lipomas are composed of mature adipocytes, whereas fibromas show abundant collagenous stroma. Schwannomas display characteristic patterns and strong S100 immunohistochemical positivity.

Immunohistochemistry remains essential for correct classification: smooth-muscle actin and desmin in leiomyomas, S100 in schwannomas, CD31 and CD34 in vascular lesions, and a low Ki-67 proliferative fraction in many benign forms. Overall, these lesions are biologically stable and lack metastatic potential, but may cause significant symptoms through mass effect or local complications, making accurate diagnostic classification essential.

The clinical manifestations of benign esophageal tumors depend mainly on lesion size, location along the organ and growth pattern. Many of these neoplasms remain asymptomatic for prolonged periods, particularly when small, and are discovered incidentally during endoscopic or radiologic examinations performed for other reasons.

The most frequent symptom is dysphagia, which tends to develop slowly and progressively. Unlike malignant neoplasms, dysphagia caused by benign tumors is often intermittent and relatively stable over time, resulting from compression or an intraluminal mass rather than infiltrative stenosis. Patients initially report difficulty swallowing solid foods, with a foreign-body sensation or delayed passage of the bolus, sometimes accompanied by spontaneous dietary adaptations.

Retrosternal pain is less common and, when present, is generally a pressure-like or intermittent discomfort related to distension of the wall or altered esophageal motility. Larger leiomyomas may cause secondary esophageal spasm with pain triggered by swallowing. Regurgitation and sialorrhea may occur when there is significant functional obstruction of the lumen or food stasis proximal to the lesion.

Certain entities have more characteristic clinical profiles. Large pedunculated fibrovascular polyps may cause intermittent dysphagia and regurgitation of the polyp into the pharynx, which in extreme cases may create a risk of airway obstruction. Vascular lesions may be associated with chronic bleeding and iron-deficiency anemia, whereas lipomas and small subepithelial nodules often remain silent until they become large or cause local complications.

Bleeding is uncommon overall but may occur if the overlying mucosa ulcerates or in the presence of hemangiomas and vascular malformations, resulting in chronic anemia or, more rarely, episodes of hematemesis. Respiratory symptoms may develop because of compression, microaspiration related to stasis or regurgitation, particularly in frail patients or those with concomitant motility disorders.

Physical examination findings are often limited and indirect. Symptomatic disease may be associated with signs of weight loss, dehydration or anemia. The onset or progression of dysphagia nevertheless requires thorough evaluation because similar clinical presentations may be caused by lesions with different biological behavior or by concomitant esophageal disease.

The diagnostic work-up of benign esophageal tumors begins with clinical suspicion based on persistent symptoms or incidental instrumental findings and follows a sequence of investigations intended to demonstrate the nonmalignant nature of the lesion, define its histologic origin and exclude neoplastic conditions with more aggressive behavior that may produce overlapping findings. When present, symptoms include intermittent or slowly progressive dysphagia, a retrosternal foreign-body sensation, noncardiac chest pain, regurgitation or respiratory symptoms secondary to compression or food stasis. In a substantial proportion of cases, the lesion is identified incidentally during endoscopy performed for other reasons. The initial assessment aims to support a benign diagnosis without reducing vigilance for features suggesting different behavior.

Esophagogastroduodenoscopy is the reference initial investigation and the first truly discriminating specialist examination. It should be performed with high-definition equipment and accompanied by a detailed description of the lesion, including its site, size, morphology, mucosal surface and relationship with the wall. Benign esophageal tumors frequently appear as subepithelial lesions, intramural nodules or smooth-surfaced polypoid masses, often covered by intact mucosa. Systematic assessment of the entire esophagus is useful for identifying synchronous lesions and indirect signs of compressive growth.

Advanced endoscopic imaging techniques, such as NBI, BLI or FICE, have a complementary role, especially in distinguishing epithelial from subepithelial lesions. Assessment of the mucosal and vascular pattern may reinforce the hypothesis of an intramural lesion when the overlying mucosa is preserved and may guide targeted sampling when superficial abnormalities require histologic investigation.

Standard endoscopic biopsies may have limited diagnostic yield in submucosal or intramural lesions because the overlying mucosa is often normal. Nonrepresentative superficial samples may produce false-negative results and fail to provide adequate characterization. When the endoscopic appearance is suggestive but not definitive, endoscopy should be supplemented by methods that identify the layer of origin and obtain more informative tissue.

In this setting, endoscopic ultrasound has a central role in the diagnostic assessment of esophageal subepithelial lesions. EUS identifies the layer of origin, evaluates echotexture and relationships with periesophageal structures, and allows more reliable distinction among muscular, stromal, vascular and cystic lesions. In selected cases, EUS-guided fine-needle aspiration or biopsy can provide cytologic or histologic material for characterization, although yield may be limited by lesion size, composition and sample adequacy.

When adequate material is available, pathological examination permits definitive diagnosis and identification of the principal benign entities, including leiomyoma, lipoma, granular cell tumor, schwannoma, hemangioma and other mesenchymal or neurogenic lesions. Morphologic examination is integrated with targeted immunohistochemistry to confirm the nature of the lesion and distinguish benign findings from neoplasms with different behavior, including stromal tumors with variable biological potential. This integration is crucial for avoiding disproportionate treatment.

According to recommendations from endoscopy societies for the assessment of gastrointestinal subepithelial lesions, a reliable determination of benignity requires concordance among clinical evaluation, endoscopy and endoscopic ultrasound and, when obtainable, representative histologic or cytologic confirmation, together with the absence of invasive or disseminated disease. In clinical practice, the choice between surveillance and treatment depends on symptoms, documented growth, layer of origin, size and suspicious features, with diagnostic reassessment when discordant findings emerge.

Differential diagnosis remains a crucial step. Benign esophageal tumors must be distinguished from slow-growing neoplasms, such as low-risk GISTs or rare low-grade tumors, and from nonneoplastic conditions such as esophageal duplication cysts, varices, extrinsic mediastinal compression or inflammatory thickening. Integration of endoscopy, endoscopic ultrasound and radiologic imaging allows accurate definition in most cases, reserving further investigations for persistent diagnostic uncertainty.

Once the nature of the lesion has been established, subsequent investigations are directed toward assessing local extent and anatomical relationships, particularly in patients who may undergo endoscopic or surgical treatment. Contrast-enhanced computed tomography is useful for evaluating relationships with mediastinal structures in large or extramurally growing lesions. PET is not routinely indicated and is considered only in selected settings when concern persists that the lesion may not be biologically benign.

Overall, the diagnostic assessment follows a rational sequence: clinical suspicion; esophagogastroduodenoscopy; endoscopic ultrasound with possible tissue sampling; pathological definition when feasible; accurate differential diagnosis; and management planning based on symptoms, size, behavior over time and the feasibility of safe resection.

By definition, benign esophageal tumors have no metastatic capacity and are not classified using oncologic staging systems such as TNM. Nevertheless, systematic assessment of local extent, size-related characteristics and layer of origin is essential for guiding clinical management and estimating the risk of complications or symptomatic progression.

Dimensional and topographic assessment is based mainly on endoscopic ultrasound, which permits precise measurement of the lesion, definition of its layer of origin and evaluation of any compressive effect on the esophageal lumen. For large lesions or suspected extramural growth, computed tomography may complement the endoluminal information by depicting mediastinal relationships and cleavage planes.

The principal prognostic determinants are size, location and histologic type. Small, asymptomatic, slow-growing lesions generally have a favorable course and may be managed with clinical and instrumental surveillance, particularly when EUS shows no suspicious features. Conversely, large benign tumors or lesions located at critical sites may cause significant dysphagia, pain or respiratory complications and require therapeutic intervention despite the complete absence of metastatic risk.

In practical terms, management distinguishes incidental, stable lesions from symptomatic, progressive or technically high-risk lesions in which the benefit of resection outweighs procedural risks. Documented growth over time, development of mucosal ulceration, bleeding or discordance between the clinical picture and instrumental findings require diagnostic reassessment and frequently an interventional strategy.

When the lesion is removed, definitive pathological examination confirms its benign nature and excludes atypical components. Complete resection is generally associated with symptom resolution and an extremely low risk of recurrence, with follow-up that is usually limited and proportionate to the treatment performed and lesion site.

Survival curves have limited relevance in these conditions because lesion-related mortality is negligible. Clinical attention is directed mainly toward symptom control, prevention of complications and preservation of esophageal function, with an overall favorable effect on long-term quality of life.

Treatment of benign esophageal tumors is guided mainly by histologic type, lesion size, location, symptoms and complication risk rather than by an oncologically radical objective. These lesions comprise a heterogeneous group of entities, including leiomyomas, lipomas, fibrovascular polyps, squamous papillomas, cysts and other rare benign formations, characterized by noninfiltrative biological behavior and absence of metastatic potential. The therapeutic approach must be individualized and discussed within a multidisciplinary setting, balancing the clinical benefit of intervention against procedural risk and functional impact.

For small asymptomatic lesions, particularly when benignity is supported by endoscopy and endoscopic ultrasound and there is no evidence of growth or complications, active observation is appropriate. Immediate treatment is not indicated, and management is based on periodic clinical and endoscopic monitoring to detect changes in size or the onset of symptoms. This strategy is particularly applicable to small leiomyomas and other subepithelial lesions that remain stable over time.

When a benign tumor is symptomatic, particularly in the presence of dysphagia, retrosternal pain, regurgitation, bleeding or mechanical complications, treatment is indicated. In these settings, endoscopic resection is often the first-line option for accessible intraluminal or submucosal lesions. Techniques such as endoscopic mucosal resection or endoscopic submucosal dissection allow complete removal with reduced invasiveness, preserving esophageal function and enabling rapid recovery.

Selection of lesions suitable for endoscopic treatment requires accurate assessment of depth of origin, size and relationships with the deeper layers of the esophageal wall. Lesions arising from the muscularis propria, such as some larger leiomyomas, may carry a higher risk of perforation if treated endoscopically and require careful selection or advanced techniques performed in highly experienced centers.

Surgery is indicated for large benign tumors, lesions with extraluminal growth or cases in which endoscopic resection is not technically feasible or safe. The aim is complete removal while preserving esophageal continuity and minimizing functional impairment. For esophageal leiomyomas, surgical enucleation is often the preferred technique because it removes the tumor while preserving the overlying mucosa.

Surgical approaches may be minimally invasive, including thoracoscopic or robotic techniques, with potential advantages in reducing surgical trauma and recovery time. The choice of approach depends on the lesion’s location along the esophagus, its size and the center’s expertise. Extended esophageal resection is rarely necessary for benign tumors and is reserved for exceptional cases involving very large lesions or associated complications.

In particular situations, such as large pedunculated fibrovascular polyps, treatment is indicated even in the absence of severe symptoms because of the risk of acute complications such as regurgitation into the pharynx and aspiration. Removal may be performed endoscopically or surgically depending on stalk size and mass extent.

Systemic therapies and radiotherapy have no role in the treatment of benign esophageal tumors. The therapeutic objective remains symptom resolution and prevention of complications while avoiding treatment disproportionate to the nonmalignant nature of the disease.

Nutritional support is a cross-cutting component of management, particularly in patients with prolonged dysphagia or pre-treatment weight loss. Preoperative nutritional assessment and post-procedural support help reduce complication risk and promote optimal functional recovery.

Follow-up and post-treatment surveillance of benign esophageal tumors have different aims from those used for malignant neoplasms and are directed mainly toward monitoring symptom resolution, detecting any local recurrence and identifying late complications of endoscopic or surgical procedures. Follow-up intensity and duration depend on lesion type, treatment performed and the patient’s clinical condition.

After complete endoscopic resection, follow-up is generally limited. Endoscopic examination several months after the procedure verifies complete mucosal healing and the absence of residual or recurrent local disease. In the absence of symptoms or suspicious findings, intensive long-term endoscopic follow-up is usually unnecessary.

After surgical treatment, particularly enucleation of leiomyomas or resection of large lesions, initial follow-up includes clinical assessment of symptoms, monitoring of swallowing function and evaluation for postoperative complications. Imaging or endoscopy is used selectively, especially when persistent dysphagia, pain or clinical suspicion of recurrence is present.

Assessment of functional sequelae is an important component of follow-up. Although uncommon, strictures, motility abnormalities or swallowing disorders may occur after extensive endoscopic procedures or surgery. In these cases, involvement of gastroenterologists, speech and swallowing therapists and rehabilitation teams enables targeted functional recovery and symptom management.

For benign tumors managed conservatively, follow-up is based on periodic clinical and endoscopic examinations, with intervals adapted to lesion size, layer of origin and stability over time. The absence of growth or new symptoms permits continued observation without intervention.

The overall duration of follow-up is generally limited and not standardized because the risk of clinically significant recurrence is low after complete resection. In successfully treated, asymptomatic patients, follow-up may be progressively spaced out or discontinued, while clinical reassessment remains indicated if new symptoms appear.

In summary, follow-up of benign esophageal tumors is intended to confirm clinical resolution and preserve esophageal function, avoiding unnecessarily invasive surveillance and maintaining an approach proportionate to the nonmalignant nature of the disease.

Long-term quality-of-life considerations are central to the overall management of benign esophageal tumors because these conditions, despite their nonmalignant behavior, may cause persistent symptoms and significant functional limitations. Their generally favorable prognosis and long life expectancy make control of chronic outcomes related both to the lesion itself and to therapeutic interventions a priority. Quality of life should therefore be assessed systematically during follow-up.

Swallowing function is a fundamental domain. Benign tumors such as leiomyomas, lipomas, fibrovascular polyps and other subepithelial lesions may cause chronic dysphagia, a foreign-body sensation or delayed food-bolus transit, particularly when located in the middle or distal esophagus. Mild functional abnormalities may persist even after surgical or endoscopic treatment and require dietary adaptations and longitudinal swallowing assessment.

Gastroesophageal reflux may be an associated disorder, particularly in patients who undergo procedures that alter motility or the anatomical continuity of the esophageal wall. Heartburn, regurgitation and nocturnal symptoms may affect daily well-being and require long-term dietary, postural and behavioral measures, which are often sufficient to achieve good symptom control.

Eating habits may undergo lasting changes. When repeated endoscopic treatments or extensive resections are required, some patients develop greater sensitivity to certain foods, early satiety or difficulty consuming large meals. Nutritional education and dietary support help maintain adequate independence and social integration.

Nutrition and body composition are generally better preserved than in malignant neoplasms, but patients with prolonged symptoms may experience unintentional weight loss or reduced muscle mass. Periodic monitoring of weight and nutritional intake allows early identification of problems and targeted intervention.

Treatment outcomes may also affect voice and respiratory function, especially for tumors located in the cervical or proximal esophagus. Mild dysphonia, chronic cough or vocal fatigue may interfere with communication and occupational activity. Targeted rehabilitation promotes functional recovery and reduces the impact on daily life.

Psychological effects should not be underestimated. Persistent symptoms, initial diagnostic uncertainty and fear of progression or recurrence may generate anxiety and alter the patient’s perception of health. Adequate information, clear communication and structured follow-up contribute to improved well-being and overall quality of life.

Overall, long-term quality of life in patients with benign esophageal tumors depends on integrated care that combines clinical and instrumental monitoring with management of functional, nutritional and psychological outcomes. In this setting, quality of life is a primary treatment objective, alongside symptom resolution and prevention of complications.

Complications of benign esophageal tumors are generally less severe than those of malignant neoplasms but may nevertheless have a meaningful clinical impact, particularly when diagnosis is delayed or repeated interventions are required. They result from the interaction among the lesion’s mechanical effects, endoscopic or surgical treatment and pre-existing functional disorders of the esophagus.

Local lesion growth may cause progressive dysphagia, odynophagia and a persistent foreign-body sensation, reducing food intake and potentially leading to malnutrition in advanced cases. Some pedunculated or large lesions may regurgitate into the pharyngeal lumen, potentially compromising the airway and creating a risk of aspiration.

Mechanical complications include ulceration of the overlying mucosa, chronic or acute bleeding and, rarely, secondary anemia. Large lesions may compress adjacent structures, causing chronic cough, retrosternal pain or respiratory symptoms.

Esophageal surgery, when indicated for large benign tumors or lesions unsuitable for endoscopic treatment, carries specific risks. Respiratory complications, particularly pneumonia, are among the main causes of postoperative morbidity. Anastomotic leakage, although less frequent than after major oncologic surgery, may occur and requires prompt treatment. Late cicatricial strictures may cause persistent dysphagia and require repeated endoscopic dilations.

Endoscopic procedures, often preferred for treating benign tumors, are not risk-free. Endoscopic resections and advanced techniques may be complicated by bleeding, perforation and acute chest pain. Dilations performed for associated strictures carry a risk of perforation, especially in fibrotic or inflamed esophagi.

Persistent functional disorders, such as impaired esophageal motility or gastroesophageal reflux, may develop in some cases and require prolonged clinical follow-up and targeted symptomatic management. Although these outcomes do not threaten survival, they may substantially affect quality of life.

Overall, management of complications in benign esophageal tumors is based on careful prevention, including accurate patient selection for the different therapeutic options, technically appropriate performance of procedures and proportionate follow-up. The principal objective is to minimize adverse-event risk, preserve esophageal function and provide the best possible long-term quality of life.